Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Qiming Tan, Seun Akindehin, Camila E. Orsso, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 103

Showing 1-25 of 103 citing articles:

Signaling pathways in obesity: mechanisms and therapeutic interventions
Xue Wen, Bohan Zhang, Beiyi Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 231
The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities
Thomas A. Wadden, Ariana M. Chao, Molly Moore, et al.
Current Obesity Reports (2023) Vol. 12, Iss. 4, pp. 453-473
Open Access | Times Cited: 54
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
Clara Luna-Marco, Francesca Iannantuoni, Alberto Hermo-Argibay, et al.
Free Radical Biology and Medicine (2024) Vol. 213, pp. 19-35
Open Access | Times Cited: 24
The microbial metabolite agmatine acts as an FXR agonist to promote polycystic ovary syndrome in female mice
Chuyu Yun, Sen Yan, Baoying Liao, et al.
Nature Metabolism (2024) Vol. 6, Iss. 5, pp. 947-962
Closed Access | Times Cited: 22
Transforming obesity: The advancement of multi-receptor drugs
Christine M. Kusminski, Diego Pérez–Tilve, Timo D. Müller, et al.
Cell (2024) Vol. 187, Iss. 15, pp. 3829-3853
Closed Access | Times Cited: 22
Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
Christian Hölscher
Neuropharmacology (2024) Vol. 253, pp. 109952-109952
Open Access | Times Cited: 19
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Qiyuan Keith Liu
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 15
Tirzepatide: A Systematic Update
Imma Forzano, Fahimeh Varzideh, Roberta Avvisato, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14631-14631
Open Access | Times Cited: 46
Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
Stefania Chiappini, Rachel Vickers‐Smith, Daniel R. Harris, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 994-994
Open Access | Times Cited: 34
GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Sydney S. Wilbon, Mikhail G. Kolonin
Cells (2023) Vol. 13, Iss. 1, pp. 65-65
Open Access | Times Cited: 27
Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells
Yusman Manchanda, Stavroula Bitsi, Shiqian Chen, et al.
Endocrinology (2023) Vol. 164, Iss. 5
Open Access | Times Cited: 26
Anti-inflammatory benefits of semaglutide: State of the art
Habib Yaribeygi, Mina Maleki, Tannaz Jamialahmadi, et al.
Journal of Clinical & Translational Endocrinology (2024) Vol. 36, pp. 100340-100340
Open Access | Times Cited: 12
Surgery is associated with better long-term outcomes than pharmacological treatment for obesity: a systematic review and meta-analysis
Leonardo Zumerkorn Pipek, Walter Fabris-Moraes, Rodrigo Massato Nobetani, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 12
i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists
Matthew G. Romei, Brandon Leonard, Zachary Katz, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Yolanda Diz-Chaves, Zainab Mastoor, Carlos Spuch, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9583-9583
Open Access | Times Cited: 37
Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer’s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach
Xavier Morató, Vanesa Pytel, Sara Jofresa, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9305-9305
Open Access | Times Cited: 32
Activity-balanced GLP-1/GDF15 dual agonist reduces body weight and metabolic disorder in mice and non-human primates
Yuanyuan Zhang, Xinyu Zhao, Xiaona Dong, et al.
Cell Metabolism (2023) Vol. 35, Iss. 2, pp. 287-298.e4
Open Access | Times Cited: 18
Metabolic disorders in prediabetes: From mechanisms to therapeutic management
Wen-Xin Ping, Shan Hu, Jingqian Su, et al.
World Journal of Diabetes (2024) Vol. 15, Iss. 3, pp. 361-377
Open Access | Times Cited: 6
A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss
Kylie S. Chichura, Clinton Elfers, Therese S. Salameh, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 15
Giving weight to incretin-based pharmacotherapy for obesity-related sleep apnea: a revolution or a pipe dream?
Ronald R. Grunstein, Thomas A. Wadden, Julia L. Chapman, et al.
SLEEP (2023) Vol. 46, Iss. 10
Open Access | Times Cited: 13
The antiemetic actions of GIP receptor agonism
Tito Borner, Bart C. De Jonghe, Matthew R. Hayes
AJP Endocrinology and Metabolism (2024) Vol. 326, Iss. 4, pp. E528-E536
Closed Access | Times Cited: 5
Non‐clinical and first‐in‐human characterization of ECC5004/AZD5004, a novel once‐daily, oral small‐molecule GLP‐1 receptor agonist
Amina Z. Haggag, Jianfeng Xu, Laurie Butcher, et al.
Diabetes Obesity and Metabolism (2024) Vol. 27, Iss. 2, pp. 551-562
Open Access | Times Cited: 5
Unveiling the Hidden: Dissecting Liraglutide Oligomerization Dual Pathways via Direct Mass Technology, Electron-Capture Dissociation, and Molecular Dynamics
Syuan‐Ting Kuo, Zhenyu Xi, Xiao Cong, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Glucagon-like peptide-1 receptor signaling activation in alveolar type II cells enhances lung development in neonatal rats exposed to hyperoxia
T. Sun, Haiyang Yu, Dingning Zhang, et al.
Redox Biology (2025) Vol. 82, pp. 103586-103586
Open Access
Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial
Theresa Hunter, Dachuang Cao, Xiaotian Michelle Zhang, et al.
Diabetes Therapy (2025)
Open Access
Page 1 - Next Page

Scroll to top